Methylene Blue Side Effects and Precautions

Introduction to Methylene Blue Risks

• Methylene blue is generally well-tolerated at therapeutic doses, but carries serious, potentially life-threatening risks in specific patient populations, particularly those with G6PD deficiency, those taking serotonergic medications, pregnant women, and patients with renal failure 1, 2

Common/Benign Side Effects

• The American Journal of Hematology reports that methylene blue commonly causes blue-green discoloration of urine and stool at therapeutic doses, which is harmless and resolves after medication cessation 3, 4

Serious and Life-Threatening Adverse Effects

• Methylene blue is absolutely contraindicated in patients with G6PD deficiency because it can cause severe, potentially fatal hemolytic anemia, according to the American Journal of Hematology 1, 5, 6, 7, 2, 8
• The American Journal of Hematology recommends that all patients should ideally be tested for G6PD deficiency before methylene blue administration 1, 5, 6, 7, 2
• Methylene blue can cause hemolysis and methemoglobinemia in non-G6PD-deficient infants, particularly in premature infants, as reported by the American Journal of Hematology 1, 2
• The American Journal of Hematology states that methylene blue can precipitate life-threatening serotonin syndrome in patients taking selective serotonin reuptake inhibitors (SSRIs) or other serotonergic antidepressants 1, 5, 2
• Methylene blue should be used with extreme caution in pregnant women due to concerns about teratogenicity and possible intestinal atresia, according to the American Journal of Hematology 1, 6, 2

Dose-Dependent Toxicity

• Toxic levels are reached at total doses >7 mg/kg, as reported by the American Journal of Hematology 1, 5, 6, 7, 2, 8, 9, 10
• The American Journal of Hematology warns that worsening methemoglobinemia can occur with repeated doses due to a rebound phenomenon 1, 5, 6, 7, 2, 8, 9, 10

Critical Pitfalls to Avoid

• The American Journal of Hematology advises to never administer methylene blue without screening for G6PD deficiency when time permits 1, 7, 2
• The American Journal of Hematology recommends to always obtain medication history for SSRIs and serotonergic drugs before administration 1, 2
• The American Journal of Hematology warns to not exceed 7 mg/kg total dose to avoid toxicity 1, 5, 6, 7, 2
• The American Journal of Hematology suggests to use alternative treatments (ascorbic acid, exchange transfusion) in G6PD-deficient patients 1, 5, 6, 7, 2
• The American Journal of Hematology advises to exercise extreme caution in pregnant women, neonates, and patients with renal failure 1, 6, 2